Clinical trials: Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Condition Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Funder type Industry (pharma, biotech, devices)
Hypercholesterolemia
Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy
The purpose of this research study is to see how ETC-1002 is tolerated in the body and how ETC-1002 affects the levels of LDL-C (bad cholesterol) in patients receiving ongoing statin therapy.
- Trial name
- NCT02072161
- Testing
- ETC-1002, Statin Therapy
- Where
- 40 sites in United States
- Volunteers
- 133 people
- Sponsor
- Esperion Therapeutics, Inc.
Cardiovascular Diseases, Dyslipidemia
Additional KIF6 Risk Offers Better Adherence to Statins
Many patients prescribed statins to lower their cholesterol stop taking their statin over time. The purpose of this study is to determine whether providing subjects their KIF6 carrier status (associated with increased…
- Trial name
- AKROBATS (NCT01068834)
- Testing
- KIF6 genetic test
- Where
- United States
- Volunteers
- 1,282 people
- Sponsor
- Medco Health Solutions, Inc.
Hypercholesterolemia
A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy
Primary Objective: To demonstrate the superiority of the single pill combination (SPC) ezetimibe 10 mg/rosuvastatin 10 mg (E10/R10) compared to rosuvastatin 10 mg (R10), in the reduction of low density lipoprotein cholesterol…
- Trial name
- ROZEL (NCT04669041)
- Testing
- Rosuvastatin, SPC ezetimibe/rosuvastatin, Rosuvastatin active capsule
- Where
- 40 sites in China
- Volunteers
- 305 people
- Sponsor
- Sanofi
Cardiovascular Risk
C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS)
To demonstrate a higher percent rate of achieved target lipid goals among patients at high cardiovascular risk using more potent lipid-lowering treatment options including high-potency statins and combination therapies.
- Trial name
- C2 -CORVUS (NCT00921752)
- Where
- 26 sites in Hungary
- Volunteers
- 1,500 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Hypertriglycemia
Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia
Assess efficacy and safety of Omacor® 4g with statin treatment for lowering TG levels in subjects with type 2 Diabetes combined with hyperlipidemia
- Trial name
- NCT02305355
- Testing
- Omega-3-acids ethylesters 90 4g, Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Kuhnil Pharmaceutical Co., Ltd.
Dyslipidaemias, Dyslipidemias
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin
This study investigates the safety, pharmacokinetics and effects of GSK1292263 when taken alone or when co-dosed with atorvastatin to subjects with dyslipidemia.
- Trial name
- NCT01218204
- Testing
- 10mg atorvastatin, 80mg atorvastatin, 100mg GSK1292263
- Where
- 21 sites in United States
- Volunteers
- 287 people
- Sponsor
- GlaxoSmithKline
Atherosclerotic Cardiovascular Disease
A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease
This study looks at how well a new medicine, NNC0385-0434, works to lower blood cholesterol levels. Participants will either get NNC0385-0434 as a tablet (a potential new medicine), or placebo as a tablet (a dummy medicine that…
- Trial name
- NCT04992065
- Testing
- NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, NNC0385-0434 A 100 mg
- Where
- 44 sites in United States, Belgium and 5 more
- Volunteers
- 267 people
- Sponsor
- Novo Nordisk A/S
Mixed Dyslipidemia
An Observational Study on the Identification of Prescription Patterns of STAFEN Cap
An observational study on the identification of prescription patterns of STAFEN Cap., changes in blood lipid concentration, and statin-related muscle symptoms in Korean patients with mixed dyslipidemia
- Trial name
- NCT06204380
- Where
- South Korea
- Volunteers
- 4,000 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Hypercholesterolaemia, Hyperlipidaemia
TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)
In patients with primary hypercholesterolemia treated with a statin and with ldl-c above the recommended target goal (esc 2003 recommendations ldl>=1.15 g/l) to compare the efficacy and the safety of ezetrol added to ongoing…
- Trial name
- NCT00328523
- Testing
- MK-0653, ezetimibe, Duration of Treatment: 3 months
- Volunteers
- 1,496 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia
The present study is assessing the efficacy and safety of AVE5530 (25 mg and 50 mg) in add-on to ongoing statin treatment in a double-blind manner in comparison with placebo, in the management of patients with primary…
- Trial name
- NCT00729027
- Testing
- 25 mg/day AVE5530, 50 mg/day AVE5530
- Where
- 16 sites in United States, Australia and 14 more
- Volunteers
- 1,015 people
- Sponsor
- Sanofi
Dyslipidemia
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)
This study will evaluate the effects of anacetrapib (MK-0859) on low-density lipoprotein-cholesterol (LDL-C) when compared to placebo in Japanese participants with dyslipidemia when added to an existing statin-modifying therapy.
- Trial name
- NCT01760460
- Testing
- Anacetrapib
- Volunteers
- 307 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia
Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)
Evaluate the safety of the long-term (1 year) coadministration of ezetimibe and simvastatin in patients with hypercholesterolemia who have not reached low density lipoprotein (LDL)-cholesterol target with…
- Trial name
- NCT00653523
- Testing
- Ezetimibe, Simvastatin
- Volunteers
- 151 people
- Sponsor
- Organon and Co
Metabolic Syndrome
Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule)
The purpose of this study was to assess the incidence rate of the major adverse cardiovascular events (MACE) and safety of fenofibrate (Lipilfen capsule) add-on statin therapy in patients who have history of acute myocardial…
- Trial name
- NCT02069717
- Testing
- Not applicable-observational study
- Where
- South Korea
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Hypercholesterolemia
A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance
This study will assess the Low-Density Lipoprotein-Cholesterol (LDL-C) lowering efficacy and safety of ETC-1002 versus placebo in participants with hypercholesterolemia and a history of statin intolerance.
- Trial name
- NCT01751984
- Testing
- ETC-1002
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- Esperion Therapeutics, Inc.
CoQ10 Blood Levels, CoQ10 Blood Levels With Statin Use
An Open Label Study Evaluating the Effectiveness of Omega Q Plus® Resveratrol at Increasing Blood Levels of CoQ10
The primary objective of this study is to assess the blood levels of Coenzyme Q10 in healthy subjects when administered Omega Q Plus® Resveratrol for 28 days.The secondary objective of the study is to determine if statin use has…
- Trial name
- NCT02415114
- Testing
- Omega Q Plus Resveratrol (with 50mg CoQ10)
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- KGK Science Inc.
Lipid Metabolism Disorder
Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia (0653-141)(COMPLETED)
Gather additional efficacy and safety (pharmacovigilance) information in the usual daily care in patients with Dyslipidemia on ezetimibe under real conditions in Colombia associated with statins.
- Trial name
- NCT00651963
- Testing
- ezetimibe
- Volunteers
- 80 people
- Sponsor
- Organon and Co
Dyslipidaemia
Statin Therapy Results in the Real World Practice in the Czech Republic
Statins are the first choice treatment of dyslipidemia, a major contributor to cardiovascular diseases. Statins also have enough evidence to demonstrate decrease of morbidity and mortality from cardiovascular diseases.
- Trial name
- STEP (NCT01055977)
- Where
- 95 sites in Czechia
- Volunteers
- 3,253 people
- Sponsor
- AstraZeneca
Coronary Atherosclerosis, Mixed Dyslipidemia
A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events
The overall objective of the trial is to evaluate the effect of the triple therapy consisting of bempedoic acid (BA), ezetimibe (EZE), and high-intensity atorvastatin or rosuvastatin on changes in coronary plaque burden and…
- Conditions
- Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia
- Trial name
- NCT07474649
- Testing
- Bempedoic acid, Ezetimibe, Rosuvastatin
- Where
- 12 sites in Germany, Italy and 1 more
- Volunteers
- 103 people
- Sponsor
- Daiichi Sankyo
Hypercholesterolemia
Efficacy and Safety Study of Pitavastatin Versus Atorvastatin to Treat Hypercholesterolemia
Statin is an effective drug to treat hyperlipidemia (hypercholesterolemia), and it rarely leads to hepatic damage to the patients with hepatic disorder. For these patients, intensive monitoring is required.
- Trial name
- PITCH (NCT01166633)
- Testing
- pitavastatin, atorvastatin
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- JW Pharmaceutical
Cardiovascular Disease
Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
The aim of this study was to estimate the number of United States (US) adults with and without prior atherosclerotic cardiovascular disease (ASCVD) and diabetes who may be eligible for inclisiran based on US National Health and…
- Trial name
- NCT07214857
- Where
- United States
- Volunteers
- 1,385 people
- Sponsor
- Novartis Pharmaceuticals